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Coevolution of cancer and stromal cellular responses

It is now becoming apparent that multiple types of stromal cells, including macrophages, mast cells, adipocytes, and 
fibroblasts make pivotal contributions to carcinogenesis. In the May 6 issue of Cell, Orimo and colleagues (Orimo et al., 
2005) show that carcinoma-associated fibroblasts can promote epithelial tumorigenesis by secreting the chemokine SDF­
1α (CXCL12). SDF-1α stimulates carcinoma cell proliferation and recruitment of endothelial precursor cells. 
A remarkable evolution in thinking about 
epithelial-derived cancer has taken place 
over the past several years. From an 
oncogene- and tumor suppressor gene­
centric view of cancer initiation and pro­
gression has come the realization that 
the tumor microenvironment is a cocon­
spirator in the carcinogenic process. The 
idea that the “host” stroma (mes­
enchyme) talks to and coevolves with the 
mutated epithelium (ectoderm) during 
progression comes as no surprise to 
developmental biologists, who have 
been dealing with instructive and permis­
sive interactions between the two com­
partments for a century. However, except 
for a couple of lonely prescient scientists, 
it is only recently that tumor biologists 
have latched on to this idea. So which 
cell types of the microenvironment are 
involved, do they have a specific “activat­
ed” state, and what molecules do they 
use to communicate? 
It is becoming accepted that the stro­
mal microenvironment contributes to 
tumorigenesis in the cancers that are 
epithelial in origin. Although the initiating 
mutation usually occurs in the epithelium, 
the event that promotes tumor progres­
sion involves the stroma. In fact, in some 
cases, the trigger for neoplastic progres­
sion may come from signals within the 
stromal microenvironment (reviewed in 
Bhowmick et al., 2004b).There are sever­
al known mechanisms for generating 
aberrant tumor-promoting stroma in vivo. 
The classic way is to expose stroma to 
tumor promoters such as phorbol esters, 
which trigger the inflammatory response. 
Another way is to irradiate the stroma. 
Genetic evidence for stromal contribution 
comes from studies on fibroblast secret­
ed protein-1 (FSP1, also called S100A4 
or mts1), which is upregulated in carcino­
ma-associated fibroblasts (CAFs) during 
tumor progression. Metastatic carcinoma 
cells injected into Fsp1−/− mice are less 
likely to form tumors and do not metasta­
size. Interestingly, coinjection of Fsp1+/+ 
fibroblasts with the tumor cells restores 
tumor development and metastasis 
(Grum-Schwensen et al., 2005). This 
suggests that Fsp1, which is secreted by 
the fibroblasts, alters the stromal 
microenvironment, making it more favor­
able for tumor progression. In contrast, 
mice with a cell-specific ablation of the 
TGF-β receptor II in a subset of stromal 
fibroblasts, which renders them unre­
sponsive to TGF-β signaling, develop 
neoplasias and carcinomas in the 
absence of any additional induced muta­
tions in the epithelium (Bhowmick et al., 
2004a). This suggests that TGF-β not 
only prevents proliferation of both the 
fibroblasts and epithelial cells, but also 
somehow protects the epithelium from 
developing hyperplasias or even carcino­
mas. However, the action of TGF-β is cell 
type specific; ablation of the TGF-β 
receptor II in epithelial cells inhibits tumor 
progression (Forrester et al., 2005). 
Irradiation of the mammary gland 
stroma also induces nonreversible 
changes in the stroma that contribute to 
neoplasia: nontransformed mammary 
epithelial cells injected into irradiated 
mammary stromal fat pads have greatly 
increased tumor growth compared to 
those injected into the contralateral, non­
irradiated mammary fat pads (Barcellos-
Hoff and Ravani, 2000). 
The above-mentioned studies show 
that there are both tumor-promoting and 
tumor-inhibiting activities mediated by 
CAFs. Now, Orimo and coworkers (Orimo 
et al., 2005) have identified another 
mechanism whereby stromal CAFs can 
promote tumorigenesis, through the 
secretion of stromal cell-derived factor 1α 
(SDF-1α, also known as CXCL12). SDF­
1α acts directly on the mammary carcino­
ma cells stimulating proliferation through 
Figure 1. Molecular mediators of stromal-
epithelial interactions in tumorigenesis 
The cells in the tumor tissue communicate 
during tumor progression through the secre-
tion of growth factors, chemokines, and 
cytokines. 
A: Examples of stimulators of tumorigenesis 
secreted by one cell type and acting on 
another. 
B: TGF-β is unique in its ability to both pro-
mote and inhibit tumorigenesis, depending 
on the cell type it is acting on. CAFs, carcino-
ma-associated fibroblasts; VEGF, vascular 
endothelial growth factor; SDF-1α, stromal 
derived factor 1α; FSP-1, fibroblast-specific 
protein-1; HGF, hepatocyte growth factor; 
MSP, macrophage-stimulating protein; EGF, 
epidermal growth factor; TGF-α, transform-
ing growth factor-α; TGF-β, transforming 
growth factor-β; FGF, fibroblast growth fac-
tor; IL-6, interleukin 6; LIF, leukemia inhibitory 
factor; NGF, nerve growth factor (Bhowmick 
et al., 2004b, and references therein). 
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the SDF-1α receptor CXCR4 found on 
the cancer cells, but SDF-1α secretion 
also leads to recruitment of endothelial 
cell precursors (EPCs) to the growing 
tumor, thereby promoting angiogenesis. 
SDF-1α’s ability to recruit the EPCs and 
promote angiogenesis might be the result 
of the activation of matrix metallopro­
teinase-9 (MMP-9). SDF-1α treatment 
activates MMP-9 in bone marrow cells, 
and MMP-9−/− mice are unresponsive to 
SDF-1α-induced recruitment of the 
hematopoetic and endothelial precursor 
cells (Heissig et al., 2002). 
TGF-β, FSP-1, SDF-1α, VEGF, MMP­
9, and a number of other stromal factors 
have been implicated in epithelial tumor 
progression (Figure 1), but we do not 
know if these factors are coconspirators 
with each other, if they are additive, syner­
gistic, or are independent pathways of 
varying importance in different tumors. 
Interestingly, there are clear links between 
TGF-β1 and SDF-1, which complicates 
the interpretation of the role of CAFs: 
TGF-β1 upregulates the SDF-1/CXCL12 
receptor CXCR4 on macrophages, 
eosinophils, NK cells, T cells, and 
hematopoietic progenitor cells, thereby 
enhancing SDF-1α’s effects (e.g., Chen et 
al., 2005).Thus, TGF-β and SDF-1α likely 
act synergistically, at least when it comes 
to their effects on inflammatory cells. 
We still know very little about what 
these tumor-promoting CAFs are and 
what distinguishes them from their coun­
terpart fibroblasts found from the same 
tissue only a few centimeters away. Like 
true fibroblasts, CAFs express vimentin. 
However, they also express α-smooth 
muscle actin and can contract collagen 
gels in vitro, thus resembling myofibrob­
lasts. Thus, the origin of these cells is 
unclear. They could be derived from 
fibroblasts, fibroblast precursors, myofi­
broblasts, or a different cell type, such as 
preadipocytes or smooth muscle cells. 
Interestingly, the CAFs isolated by Orimo 
and coworkers maintain their ability to 
stimulate tumor progression through 
several cell passages, but show no 
evidence of genetic alterations and 
senesce normally in culture. Thus, the 
CAFs could not have evolved from the 
cancer cells, and the signals in the early 
tumor that result in their expansion are 
not required to preserve the characteris­
tics of the cells. It is tempting to specu­
late that the CAFs are an expanded 
population of an early developmental 
precursor initially present in the normal 
precancerous mammary gland, a popu­
lation that expands in response to sig­
nals from the cancer cells. 
While we have focused on the contri­
butions of the fibroblast-like cells, the 
CAFs, to tumor evolution, both the 
fibroblasts and the carcinoma cells exist 
in the context of a tumor “tissue” with 
multiple cell types, including leukocytes, 
endothelial cells, and adipocytes, all of 
which have been shown to adapt to, coe­
volve with, and shape tumor progres­
sion. In animal experiments, it has 
profound effects on tumor progression 
when one of these stromal cell types is 
removed or their behavior changed by 
genetic alterations.Thus, we can deduce 
that signaling takes place between virtu­
ally all of the cell types in the tumor tis­
sue, although only a limited number of 
signaling molecules involved in the com­
munications between cell types within 
the tumor tissue has been identified 
(Figure 1). Orimo and colleagues used a 
xenograft model employing immune­
compromised mice for their studies and 
did not address signaling links between 
CAFs and leukocytes mediated by SDF­
1α. The regulation of tumor progression 
by leukocytes has been shown in numer­
ous studies, and SDF-1α is a well-estab­
lished chemoattractant for leukocytes. 
Thus, it is very likely that SDF-1α would 
have additional effects acting through 
leukocytes if studied in the context of a 
full cellular immune response. 
Significantly, genes expressed by the 
stromal cells in the tumors are prognostic 
predictors in human breast cancer (West 
et al., 2005). Thus, the stromal contribu­
tion to cancer is not only of academic 
interest to a cancer biologist working with 
animal models; it has huge relevance for 
cancer patients and offers great potential 
for treatment of cancer. Whereas a nor­
mal stroma may protect the epithelium 
from tumorigenesis, an aberrant stroma 
can initiate tumorigenesis. Stunningly, 
restoration of abnormal microenviron­
mental signaling can reverse the malig­
nant phenotype even though the tumor 
cells retain all their mutations (Bissell and 
Radisky, 2001). We are still far from 
developing strategies to interrupt signal­
ing between CAFs and the carcinoma 
cells. However, drugs that target endothe­
lial cells and thereby inhibit angiogenesis 
are showing significant effects on cancer 
patient survival, even if the first genera­
tion of drugs is no magical bullet to cure 
cancer. The complex signaling network 
within the cancer cells has long been 
studied and is the target of drug develop­
ment. The complex signaling between 
cells in the tumor tissue could be next. 
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